Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-NTF
- Development stage
- Phase 3
- Lead developer
- BrainStorm Cell Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
MSC-NTF (NurOwn) is an investigational cell therapy consisting of autologous, bone marrow-derived mesenchymal stem cells (MSCs) that are expanded and differentiated ex vivo to secrete high levels of neurotrophic factors (NTFs). The process involves collecting a patient's own bone marrow, isolating and expanding the MSCs, and then inducing them under patented conditions to produce NTFs. These modified cells are then administered intrathecally (into the spinal fluid), where they are intended to deliver neuroprotective and immunomodulatory effects directly at sites of neuronal damage. The primary mechanism is believed to be the secretion of multiple NTFs that support neuron survival, modulate immune responses in the central nervous system, promote remyelination, and potentially slow or stabilize disease progression. Developed by BrainStorm Cell Therapeutics, this therapy is primarily being investigated for amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis (MS)[1][2][4][5].
- Brand names
- NurOwn
- Other names
- autologous mesenchymal stem cells secreting neurotrophic factorsautologous MSC-NTF cellsmesenchymal stromal cells secreting neurotrophic factors
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)RET (Rearranged during transfection receptor tyrosine kinase)NTRK2 (Tropomyosin-related kinase receptor type B)VEGFR2 (Vascular endothelial growth factor receptor 2)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on MSC-NTF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSC-NTF.